Prilocaine_721-50-6_DataSheet_MedChemExpress
Primidone_125-33-7_DataSheet_MedChemExpress
Product Name:Primidone CAS No.:125-33-7Cat. No.:HY-B0339Product Data SheetMWt:218.25Formula:C12H14N2O2Purity :>98%DMSO 44 mg/mL; Water <1 mg/mL Solubility:Mechanisms:Biological Activity:P i id i ti l t f th i idi di lPathways:Membrane Tranporter/Ion Channel; Target:GABA ReceptorPathways:Neuronal Signaling; Target:GABA Receptor SO g/;ate g/Primidone is an anticonvulsant of the pyrimidinedione class.Target: GABA Receptor Primidone is an anticonvulsant of the pyrimidinedione class, the active metabolites of which,phenobarbital (minor) and phenylethylmalonamide (PEMA) (major), are also anticonvulsants. It is believed to work via interactions with voltage-gated sodium channels which inhibit high-frequency repetitive firing of action potentials [1]. The effect of primidone in essential tremor is not mediated by PEMA.[76] The major metabolite, phenobarbital, is also a potent anticonvulsant in its own right and likely contributes to primidone's effects in many forms of epilepsy [2]. Primidone and the other enzyme-inducing anticonvulsants can cut the half-life of antipyrine roughly in half (6.2±1.9h vs.References:[1]. Macdonald, R.L. and K.M. Kelly, Antiepileptic drug mechanisms of action. Epilepsia, 1995. 36Suppl 2: p. S2-12.[2]. Calzetti, S., et al., Phenylethylmalonamide in essential tremor. A double-blind controlled study. J enzyme inducing anticonvulsants can cut the half life of antipyrine roughly in half (6.2 ± 1.9 h vs.11.2 ± 4.2 h), and increases the clearance rate by almost 70%. Phenobarbital reduces the half-life to4.8...Neurol Neurosurg Psychiatry, 1981. 44(10): p. 932-4.[3]. Perucca, E., et al., A comparative study of the relative enzyme inducing properties ofanticonvulsant drugs in epileptic patients. Br J Clin Pharmacol, 1984. 18(3): p. 401-10.Caution: Not fully tested. For research purposes onlyMedchemexpress LLC18W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S AE m a i l : i n f o @m e d c h e m e x p r e s s .c o mW e b : w w w .m e d c h e m e x p r e s s .c o m。
Naltrexone_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence.IC50 Value:Target: Opioid ReceptorNaltrexone is competitive antagonist for μ, κ, δ, and σ–opioid receptors, Naltrexone has greater oral efficacy and longer duration of action than naloxone. Naltrexone treatment caused a doubling in the density of [3H]DAMGO binding sites in both whole brainmembranes and the 7315c cell membranes. Naltrexone treatment may have slightly diminished the affinity of mu opioid receptors for[3H]DAMGO (by 1.5– to 2–fold), but the precision of the assay was inadequate to determine whether this difference was significant.Naltrexone treatment also had no effect on the potency or efficacy of guanosine 5'–O–(3–thiotriphosphate) in diminishing[3H]DAMGO binding to either whole brain or 7315c cell membranes. Naltrexone which has no SP receptor antagonistic action, not only indirectly acts on SP–ergic neurons but also causes a change in the apparent affinity of NK–1 receptor (as reflected by changes in IC50 values) in the striatum. Cellular inositol–1,4,5–trisphosphate [Ins(1,4,5)P3], quantified by a highly sensitive and selective radioreceptor mass assay, was increased in the striatum by 28% relative to control levels.References:[1]. Lobmaier PP, et al. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review. CNS Neurosci Ther. 2011 Dec;17(6):629–36.[2]. Mannelli P, Peindl KS, Wu LT. Pharmacological enhancement of naltrexone treatment for opioid dependence: a review. Subst Abuse Rehabil. 2011 Jun;2011(2):113–123.[3]. Swift R, Oslin DW, Alexander M, Forman R. Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review. J Stud Alcohol Drugs. 2011Nov;72(6):1012–8.[4]. Makowski CT, Gwinn KM, Hurren KM. Naltrexone/bupropion: an investigational combination for weight loss and maintenance. Obes Facts. 2011;4(6):489–94.[5]. Hulse GK. Improving Clinical Outcomes for Naltrexone as a Management of Problem Alcohol Use. Br J Clin Pharmacol. 2012 Sep 5. doi:10.1111/j.1365–2125.2012.04452.x.[6]. NaltrexoneProduct Name:Naltrexone Cat. No.:HY-76711CAS No.:16590-41-3Molecular Formula:C 20H 23NO 4Molecular Weight:341.40Target:Opioid Receptor; Opioid Receptor Pathway:GPCR/G Protein; Neuronal Signaling Solubility:DMSO: ≥ 31 mg/mLCaution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@ Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
Pranlukast_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :PranlukastCatalog No. :HY-B0290CAS No. :103177-37-31.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Acute toxicity, Oral (Category 4),H302Acute aquatic toxicity (Category 1),H400Chronic aquatic toxicity (Category 1),H4102.2 GHS Label elements, including precautionary statementsPictogramSignal word WarningHazard statement(s)H302 Harmful if swallowed.H410 Very toxic to aquatic life with long lasting effects.Precautionary statement(s)P264 Wash skin thoroughly after handling.P270 Do not eat, drink or smoke when using this product.P273 Avoid release to the environment.P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell.P330 Rinse mouth.P391 Collect spillage.P501 Dispose of contents/ container to an approved waste disposal plant.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:ONO 1078; ONO⁻1078Formula:C27H23N5O4Molecular Weight:481.50CAS No. :103177-37-34. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGUN number: 3077Class: 9Packing group: IIIEMS-No: F-A, S-FProper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.Marine pollutant: Marine pollutantIATAUN number: 3077Class: 9Packing group: IIIProper shipping name: Environmentally hazardous substance, solid, n.o.s.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
Alvespimycin_467214-20-6_DataSheet_MedChemExpress
Product Name:Alvespimycin CAS No.:467214-20-6Cat. No.:HY-10389Product Data SheetMWt:616.75Formula:C32H48N4O8Purity :>98%Solubility:DMSOMechanisms:Biological Activity:Alvespimycin (17-DMAG; KOS-1022; NSC 707545) is a potent, water-soluble HSP90 inhibitor withPathways:Cell Cycle/DNA Damage; Target:HSP Pathways:Metabolism/Protease; Target:HSP p y (;;)p ,IC50 of 62 nM.IC50 Value: 62 nMTarget: HSP90in vitro: 17-DMAG displays ~2 times potency against human Hsp90 than 17-AAG, with IC50 of 62nM versus 119 nM. In SKBR3 and SKOV3 cells which over-express Hsp90 client protein Her2, 17-DMAG causes down-regulation of Her2 with EC50 of 8 nM and 46 nM, respectively, as well asinduction of Hsp70 with EC50 of 4 nM and 14 nM, respectively, leading to significant cytotoxicity with GI50 of 29 nM and 32 nM, respectively, consistent with Hsp90 inhibition. 17-DMAG in combination ith i t t i ti ll i d t i f th lt d MCL ll ll i MCL References:[1]. Smith V et parison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin(17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models Cancer Chemother Pharmacol 2005Aug;56(2):126with vorinostat synergistically induces apoptosis of the cultured MCL cells as well as primary MCL cells, more potently than either agent alone, by markedly attenuating the levels of cyclin D1 andCDK4, as well as of c-Myc, c-RAF and Akt. in vivo: 17-DMAG treatme...client proteins in melanoma models Cancer Chemother Pharmacol. 2005 Aug;56(2):126[2]. Jhaveri K, Miller K, Rosen L, Schneider B, Chap L, Hannah A, Zhong Z, Ma W, Hudis C, Modi S.A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17DMAG) in the Treatment of Advanced Solid Tumors.Clin Cancer Res. 2012 Aug 3.[3]. Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, Peachey H, Aherne W, de Bono JS, Raynaud F, Workman P, Judson I.A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.Clin Cancer Res. 201...Caution: Not fully tested. For research purposes onlyMedchemexpress LLC。
Cholesterol_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:Cholesterol is the major sterol in mammals, and its importance in fundamental cellular processes is becoming more appreciated.IC50 value:Target:In vitro: GT1–7 hypothalamic cells subjected to cholesterol depletion in vitro produced 20–31% reductions in cellular cholesterol content, similar to the decrease in cholesterol synthesis observed in diabetes [1].In vivo:References:[1]. Laverdy OG, et al. Effects of glycemic control upon serum lipids and lipid transfers to HDL in patients with type 2 diabetes mellitus: novel findings in unesterified cholesterol status. Experimental and Clinical Endocrinology & Diabetes, 2015, 123(4):232–239[2]. Sandy Huey–Jen Hsu, et al. Validation of the Estimation of Low–density Lipoprotein Cholesterol by the Modified Friedewald Equation in Ethnic Chinese Adults Living in Taiwan. Internal Medicine, 54: 2291–2297, 2015[3]. Fukui K, et al. Effect of Cholesterol Reduction on Receptor Signaling in Neurons. J Biol Chem. 2015 Sep 14.Product Name:Cholesterol Cat. No.:HY-N0322CAS No.:57-88-5Molecular Formula:C 27H 46O Molecular Weight:386.65Target:Estrogen Receptor/ERR Pathway:Others Solubility:DMSO: 0.79 mg/mL (Need warming)Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@ Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
Procaine_59-46-1_DataSheet_MedChemExpress
Product Name:Procaine CAS No.:59-46-1Cat. No.:HY-B0546Product Data SheetMWt:236.31Formula:C13H20N2O2Purity :>98%Solubility:Mechanisms:Biological Activity:P i i l l th ti d f th i t hi h t th h lti l t tPathways:Others; Target:Others DMSOProcaine is a local anesthetic drug of the amino ester group, which acts through multiple targets.Target: Others Procaine is a local anesthetic of the ester type that has a slow onset and a short duration of action.Procaine (0.01-100 microM) inhibited the 5-HT3 receptor-mediated inward current in the whole-cell patch clamp recording. Procaine appears to produce a competitive inhibition on 5-HT3receptors with a KD of 1.7 microM [1]. Procaine is a DNA-demethylating agent that produces a 40%reduction in 5-methylcytosine DNA content as determined by high-performance capillaryelectrophoresis or total DNA enzyme digestion. Procaine can also demethylate denselyhypermethylated CpG islands.Procaine also has growth-inhibitory effects in these cancer cells,References:[1]. Fan, P. and F.F. Weight, Procaine impairs the function of 5-HT3 receptor-ion channel complex inrat sensory ganglion neurons. Neuropharmacology, 1994. 33(12): p. 1573-9.[2]. Villar-Garea, A., et al., Procaine is a DNA-demethylating agent with growth-inhibitory effects in hypermethylated CpG islands. Procaine also has growth inhibitory effects in these cancer cells,causing mitotic arrest [2]. Procaine functions as an excitant of limbic system cells, and that procaine alters synapti...human cancer cells. Cancer Res, 2003. 63(16): p. 4984-9.[3]. Adamec, R.E. and C. Stark-Adamec, The effects of procaine HCl on population cellular and evoked response activity within the limbic system of the cat. Evidence for differential excitatoryaction of procaine in a variety of limbic circuits. Prog Neuropsychopharmacol Biol Psychiatry, 1987.11(4): p. 345-64.Caution: Not fully tested. For research purposes onlyMedchemexpress LLC18 W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S AE m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。
Setmelanotide_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:Setmelanotide (RM–493;BIM–22493;IRC–022493) is a melanocortin 4 receptor (MC4R ) agonist with an EC 50 of 0.27 nM for human MC4R.IC50 & Target: EC50:3.9 nM (hMC1R), 10 nM (hMC3R), 2.1 nM (hMC4R)[1]Ki: 5.8 nM (hMC1R), 5.3nM (hMC3R), 0.27 nM (hMC4R)[1]In Vitro: Melanocortin receptor agonists act in the brain to regulate food intake and body weight and, independently of these actions, affect insulin sensitivity. Setmelanotide exhibits agonist activity to human and rat MC4R with K i s of 2.1 and 2.7 nM and EC 50s of 0.27 and 0.28 nM, respectively [1].In Vivo: Inhibition of refeeding after an overnight fast by BIM–22493 is dependent on functional MC4R, and does not require MC3R.BIM–22493 acutely improves glucose homeostasis. Lep ob /Lep ob mice treated with BIM–22493 exhibits significantly improvedglucose clearance when compared to controls. Chronic BIM–22493 treatment was associated with significantly lower levels of serum insulin, glucose and HOMA–IR values, suggesting an improvement in insulin sensitivity [1]. Treatment with setmelanotide results in transient decreases in food intake (35%), with persistent weight loss over 8 weeks of treatment (13.5%) in a diet–induced obese nonhuman primate model [2].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[1]Cell membranes are prepared from CHO–K1 cells stably expressing the human melanocortin receptor subtypes(MC1R, MC3R, MC4R and MC5R). They are incubated at 1–10 μg protein/well in 50 mM Tris–HCl, pH 7.4, containing 0.2% BSA, 5 mM MgCl 2, 1 mM CaCl 2 and 0.1 mg/mL bacitracin, with increasing concentrations of setmelanotide and 0.1–0.3 nM [125I]–NDP–α–MSH for 90–120 min at 37°C, depending on the receptor subtype. Bound from free [125I]–NDP–α–MSH is separated by filtration through GF/C glass fiber filters presoaked with 0.1 % (w/v) PEI. Filters are washed three times with 50 mM Tris–HCl, pH 7.4,at 0–4°C and assayed for radioactivity using Perkin Elmer Topcount scintillation counter [1].Animal Administration:[1]Mouse: Mice are weighed. Baseline blood glucose is measured and 2 g/kg body weight of D–glucose injected by i.p. BIM–22493 is administered chronically at a dose of 300 nmol/kg/day for 14 days by sc. osmotic pump. Controls are administered with 0.9% saline during the same period. Blood glucose is measured at 15, 30, 60, and 120 minutes post injection [1].References:[1]. Kumar KG, et al. Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R– and MC4R–deficient C57BL/6J mice. Peptides.2009 Oct;30(10):1892–900.[2]. Kievit P, et al. Chronic treatment with a melanocortin–4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascularProduct Name:Setmelanotide Cat. No.:HY-19870CAS No.:920014-72-8Molecular Formula:C 49H 68N 18O 9S 2Molecular Weight:1117.31Target:Others Pathway:Others Solubility:DMSOfunction in diet–induced obese rhesus macaques. Diabetes. 2013 Feb;62(2):490–7.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
Emamectin_Benzoate_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:Emamectin Benzoate works as a chloride channel activator by binding gamma aminobutyric acid (GABA) receptor andglutamate–gated chloride channels disrupting nerve signals within arthropods.Target: GABA ReceptorEmamectin Benzoate stimulates the release of GABA from the synapses between nerve cells and while additionally increasing GABA's affinity for its receptor on the post–junction membrane of muscle cells in insects and arthropods.PROTOCOL (Extracted from published papers and Only for reference)Animal administration [1]Emamectin benzoate was dissolved in acetone to various concentrations (200, 100, 50, 25, 10, 5.0 and 1.0 mg a.i./L). The nematicidal efficacy of Emamectin benzoate against J2 of M. incognita was determined in aqueous tests. Emamectin benzoate treatments (200,100, 50, 25, 10, 5.0 and 1.0 mg a.i./L) were prepared in acetone + distilled water (10: 90% by volume), and distilled water, as well as a mixture of water with acetone at concentrations equivalent to those in the treatment wells, were used as controls. Then 1 mL ofsolution and 1 mL of root–knot nematodes J2 (containing average 150 J2) was added to each well of a 24–well plate. Well plates were wrapped with parafilm, placed in plastic zip–lock bags and stored in aluminum foil pans covered with another pan to keep them dark.Units were kept at 25°C. After 48 h, the relative percentages of the motile and immotile J2 were evaluated using an invertedmicroscope at 40×magnification. Furthermore, nematodes were moved to distilled water after washing in tap water through a 20 μm pore screen to remove excess chemicals. To confirm the nematicidal activity of emamectin benzoate, immobile 30 J2 from each treatment were collected from the above experiments, transferred to tissue culture plates filled with water, and monitored for 12 h.The experiments had five replications and were repeated three times.References:[1]. Cheng X, et al. Effect of Emamectin Benzoate on Root–Knot Nematodes and Tomato Yield. PLoS One. 2015 Oct 28;10(10):e0141235.Product Name:Emamectin (Benzoate)Cat. No.:HY-B0837CAS No.:155569-91-8Molecular Formula:C 104H 154N 2O 28Molecular Weight:1880.33Target:GABA Receptor; GABA Receptor Pathway:Neuronal Signaling; Membrane Transporter/Ion Channel Solubility:DMSO: ≥ 31 mg/mLCaution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@ Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
矿产资源开发利用方案编写内容要求及审查大纲
矿产资源开发利用方案编写内容要求及《矿产资源开发利用方案》审查大纲一、概述
㈠矿区位置、隶属关系和企业性质。
如为改扩建矿山, 应说明矿山现状、
特点及存在的主要问题。
㈡编制依据
(1简述项目前期工作进展情况及与有关方面对项目的意向性协议情况。
(2 列出开发利用方案编制所依据的主要基础性资料的名称。
如经储量管理部门认定的矿区地质勘探报告、选矿试验报告、加工利用试验报告、工程地质初评资料、矿区水文资料和供水资料等。
对改、扩建矿山应有生产实际资料, 如矿山总平面现状图、矿床开拓系统图、采场现状图和主要采选设备清单等。
二、矿产品需求现状和预测
㈠该矿产在国内需求情况和市场供应情况
1、矿产品现状及加工利用趋向。
2、国内近、远期的需求量及主要销向预测。
㈡产品价格分析
1、国内矿产品价格现状。
2、矿产品价格稳定性及变化趋势。
三、矿产资源概况
㈠矿区总体概况
1、矿区总体规划情况。
2、矿区矿产资源概况。
3、该设计与矿区总体开发的关系。
㈡该设计项目的资源概况
1、矿床地质及构造特征。
2、矿床开采技术条件及水文地质条件。